Metastatic melanoma treatment: Combining old and new therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metastatic melanoma treatment: Combining old and new therapies

Published:2016-02 Issue: Volume:98 Page:242-253
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Davey Ryan J.,Westhuizen Andre van der,Bowden Nikola A.

Funder

Hunter Melanoma Foundation, Australia

Australian National Health & Medical Research Council

Cancer Institute of New South Wales, Australia

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference177 articles.

1. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy;Abbotts;Oncotarget,2014

2. Genetic alterations of PTEN in human melanoma;Aguissa-Toure;Cell. Mol. Life Sci.,2012

3. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?;Albino;Nature,1984

4. Immunotherapy for melanoma: current status and perspectives;Alexandrescu;J. Immunother.,2010

5. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, opem label pahse 2 study;Ascierto;Lancet Oncol.,2013

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Joinpoint regression analysis of recent trends in desmoplastic malignant melanoma incidence and mortality: 15-year multicentre retrospective study;Archives of Dermatological Research;2024-05-25

2. Identification of Molecular Subtypes Based on Tertiary Lymphoid Structure in Skin Cutaneous Melanoma;J BIOL REG HOMEOS AG;2024

3. A Narrative Review of Current Knowledge on Cutaneous Melanoma;Clinics and Practice;2024-01-26

4. A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma;International Journal of Molecular Sciences;2023-05-07

5. Can Baseline [¹⁸F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study;Cancer Biotherapy and Radiopharmaceuticals;2023-05-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3